Observes real-world use of KarXT in adults with schizophrenia
Studies how adults with schizophrenia fare on KarXT in routine care.
Plain-language title generated from the registry record
Registry title: Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Key facts
- Where
- Anaheim, Apple Valley, Atlanta, Austell, Austin, Bloomfield Township, Bonita Springs, Bryant, Buffalo, Cary, Charlotte, Chino, Cordova, Crystal Lake, Dallas, Detroit, Duluth, Fort Worth, Franklin, Hagerstown, Hartford, Hialeah, Homestead, Houston, Irving, Kendall, La Palma, Las Vegas, Lincoln, Marietta, Mason, McKinney, Miami, Mission Viejo, Monsey, Nashville, Oceanside, Oklahoma City, Orange City, Orland Park, Orlando, Petersburg, Philadelphia, Redlands, Richmond, Rochester, San Antonio, San Diego, Seal Beach, Stafford, Stanford, State College, Tulsa, Warrenville, White Plains, Wilmington, Worcester, and Wyomissing, United StatesSee the 68 sites
Where in United States
- AnaheimAnaheim, United StatesNot yet recruiting
- Pamoja Advanced Nursing PracticeAnaheim, United StatesTaking people
- Apple ValleyApple Valley, United StatesNot yet recruiting
- Emory UniversityAtlanta, United StatesTaking people
- Avant PsychiatryAustell, United StatesTaking people
- AustinAustin, United StatesNot yet recruiting
- Bloomfield TownshipBloomfield Township, United StatesNot yet recruiting
- Envision Trials LLCBonita Springs, United StatesTaking people
- SanRo Clinical Research GroupBryant, United StatesTaking people
- BuffaloBuffalo, United StatesNot yet recruiting
- Magnolia Clinical Research LLCCary, United StatesTaking people
- CharlotteCharlotte, United StatesNot yet recruiting
- Inland Psychiatric Medical Group (IPMG)-ChinoChino, United StatesTaking people
- CordovaCordova, United StatesNot yet recruiting
- Crystal LakeCrystal Lake, United StatesNot yet recruiting
- DallasDallas, United StatesNot yet recruiting
- DetroitDetroit, United StatesNot yet recruiting
- DuluthDuluth, United StatesNot yet recruiting
- SCLA Management- Psymed SolutionsFort Worth, United StatesTaking people
- Psychiatric Consultants, PCFranklin, United StatesTaking people
- HagerstownHagerstown, United StatesNot yet recruiting
- HartfordHartford, United StatesNot yet recruiting
- HartfordHartford, United StatesNot yet recruiting
- Galiz ResearchHialeah, United StatesTaking people
- HomesteadHomestead, United StatesNot yet recruiting
- HoustonHouston, United StatesNot yet recruiting
- HoustonHouston, United StatesNot yet recruiting
- HoustonHouston, United StatesNot yet recruiting
- HoustonHouston, United StatesNot yet recruiting
- Pioneer Research Solutions, Inc.Houston, United StatesTaking people
- IrvingIrving, United StatesNot yet recruiting
- New Access Research & Medical Services Inc - KendallKendall, United StatesTaking people
- La PalmaLa Palma, United StatesNot yet recruiting
- Las VegasLas Vegas, United StatesNot yet recruiting
- Alivation Research, LLCLincoln, United StatesTaking people
- MariettaMarietta, United StatesNot yet recruiting
- MasonMason, United StatesNot yet recruiting
- McKinneyMcKinney, United StatesNot yet recruiting
- MiamiMiami, United StatesNot yet recruiting
- MiamiMiami, United StatesNot yet recruiting
- Banyan Behavioal Care Program - CSUMiami, United StatesTaking people
- BioResearch Partner - MiamiMiami, United StatesTaking people
- Mission ViejoMission Viejo, United StatesNot yet recruiting
- MonseyMonsey, United StatesNot yet recruiting
- NashvilleNashville, United StatesNot yet recruiting
- OceansideOceanside, United StatesNot yet recruiting
- The Rivus Wellness & Research InstituteOklahoma City, United StatesTaking people
- Medical Research of Central FloridaOrange City, United StatesTaking people
- Orland ParkOrland Park, United StatesNot yet recruiting
- OrlandoOrlando, United StatesNot yet recruiting
- PetersburgPetersburg, United StatesNot yet recruiting
- Perelman School of Medicine at the University of PennsylvaniaPhiladelphia, United StatesTaking people
- RedlandsRedlands, United StatesNot yet recruiting
- Perceptive Pharma ResearchRichmond, United StatesTaking people
- RochesterRochester, United StatesNot yet recruiting
- UT Health San Antonio - Behavioral Health and Wellness CenterSan Antonio, United StatesTaking people
- San DiegoSan Diego, United StatesNot yet recruiting
- Seal BeachSeal Beach, United StatesNot yet recruiting
- R & H Clinical Research-3727 Greenbriar DrStafford, United StatesTaking people
- StanfordStanford, United StatesNot yet recruiting
- State CollegeState College, United StatesNot yet recruiting
- TulsaTulsa, United StatesNot yet recruiting
- Amr Conventions Research - IllinoisWarrenville, United StatesTaking people
- Phillips Medical Services PLLCWhite Plains, United StatesTaking people
- PPD Virtual - PPD - USWilmington, United StatesTaking people
- WorcesterWorcester, United StatesNot yet recruiting
- WorcesterWorcester, United StatesNot yet recruiting
- WyomissingWyomissing, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07379827
- Record updated
- 2 November 2026
- Original description
The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United StatesRead full original descriptionShow less
Effectiveness and Adverse-effect Switch Evaluation
The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States
Inclusion: Participants (or caregiver/legal guardian) must have signed and dated an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written ICF or signed an electronic ICF in accordance with regulatory, local, and institutional guidelines; Adults ≥ 18 years of age at Baseline who are willing and able, in the judgement of the treating clinician, to participate in routine clinical care and follow up; Schizophrenia, confirmed by the treating clinician's judgement or physician decision to treat the patient with receiving xanomeline and trospium chloride (KarXT) for schizophrenia made prior to and independently of participation in this study. Current Antipsychotic Treatment: Participant must fall into one of the categories below:; Be within <16 weeks of initiating treatment with KarXT with intent to discontinue prior antipsychotic treatment(s) OR; On a stable regimen (dose and frequency consistent with the drug label and/or at a stable dose based on the judgement of the Investigator for at least 30 days prior to screening) of treatment with 1 or more antipsychotics with plan to discontinue and switch to treatment with KarXT from a prior antipsychotic treatments(s). NOTE: The decision to switch for reasons of safety, tolerability, and/or efficacy will be made independently by the treating clinician and/or the patient and is not dictated by the study. Participants can be enrolled during tapering/discontinuing process from prior antipsychotic treatment(s). Individuals who are not currently receiving treatment for schizophrenia are not eligible for the study. Any antipsychotic treatments must be recorded as concomitant medications; Concomitant psychiatric medications (eg, antidepressants, mood stabilizers, anxiolytics) are permitted and are recommended to remain at a stable dose during the study period.
Exclusion: Prior use of KarXT that has been discontinued for any reason prior to Baseline; Known hypersensitivity to xanomeline or trospium chloride, or history or high risk of urinary retention, gastric retention, moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment, or narrow-angle glaucoma; In the opinion of the treating clinician, unstable psychiatric or medical conditions that would prevent the participant from safely switching to KarXT. Hospitalized individuals who have been switched to KarXT or are switching treatment to KarXT are permitted to be enrolled at discharge if they are < 16 weeks from initiation of KarXT; Participation in an interventional study within the last 30 days or plans to participate in an interventional study at the time of eligibility or baseline through the study period; Participants who are pregnant, planning to become pregnant, or breastfeeding.